HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beilhack, G. F. Articles by Shizuru, J. A. Search for Related Content PubMed PubMed Citation Articles by Beilhack, G. F. Articles by Shizuru, J. A. Social Bookmarking                What's this?

Prevention of Type 1 Diabetes with Major Histocompatibility Complex–Compatible and Nonmarrow Ablative Hematopoietic Stem Cell Transplants

¹ Department of Medicine, Stanford University, Stanford, California
² Department of Pathology, Stanford University, Stanford, California

Progression to hyperglycemia in young nonobese diabetic (NOD) mice is blocked by the transplantation of hematopoietic cells mismatched at the major histocompatibility complex (MHC). Because the NOD MHC class II allele, I-A^g7, is the primary disease susceptibility gene, it is logical to conclude that MHC-mismatched hematopoietic grafts prevent diabetes by replacement of this susceptibility allele on critical hematolymphoid populations. In this report, transplantation of MHC-matched purified hematopoietic stem cells (HSCs) pre-vented diabetes development in NOD mice, demonstrating that alleles of non-MHC background genes expressed on hematopoietic cells are sufficient to disrupt the autoaggressive process. Nonmarrow ablative conditioning was 100% protective, further showing that elimination of NOD hematopoiesis, including T-cells, was not required for the graft to block diabetes pathogenesis. The current standard clinical practice of hematopoietic cell transplantation uses donor/recipient pairs that are matched at the MHC. In our view, the principles established here using an MHC-matched engineered hematopoietic graft in conjunction with nonmarrow ablative conditioning to successfully block autoimmune diabetes sufficiently reduces the morbidity of the allogeneic transplantation procedure such that a similar approach can be translated to the treatment of human autoimmune disorders.

Abbreviations: AHCT, allogeneic hematopoietic cell transplantation; APC, antigen-presenting cell; FACS, fluorescence-activated cell sorter; GVHD, graft-versus-host disease; HSC, hematopoietic stem cell; MHC, major histocompatibility complex; NK, natural killer

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Smith-Berdan, D. Gille, I. L. Weissman, and J. L. Christensen Reversal of autoimmune disease in lupus-prone New Zealand black/New Zealand white mice by nonmyeloablative transplantation of purified allogeneic hematopoietic stem cells Blood, August 15, 2007; 110(4): 1370 - 1378. [Abstract] [Full Text] [PDF]